Singapore markets open in 1 hour 8 minutes

DiaMedica Therapeutics Inc. (DMAC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.4600+0.0800 (+3.36%)
At close: 04:00PM EST
2.5400 +0.08 (+3.25%)
After hours: 05:44PM EST

DiaMedica Therapeutics Inc.

Two Carlson Parkway
Suite 260
Minneapolis, MN 55447
United States
763 612 6755

Full-time employees10

Key executives

NameTitlePayExercisedYear born
Mr. Dietrich John Pauls MBAPres, CEO & Director687.58kN/A1971
Mr. Scott B. Kellen C.A.CFO & Company Sec.370.16kN/A1965
Dr. Harry W. Alcorn Jr., Pharm.D.Sr. VP of Clinical Operations389.93kN/A1956
Dr. Edward G. Calamai Ph.D.Consulting Head of ManufacturingN/AN/AN/A
Dr. Kirsten L. Gruis M.D., M.S.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Corporate governance

DiaMedica Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.